SEP
FLNA icon

Signature Equity Partners’s Filana Therapeutics FLNA Stock Holding History

Signature Equity Partners’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.38K Hold
2,000
– – ﹤0.01% 1148
2026
Q1 		$3.38K Hold
2,000
– – ﹤0.01% 1035
2025
Q4 		$3.96K Buy
+2,000
New +$6.4K ﹤0.01% 1052

Other funds holding FLNA

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $1.92B AUM 70.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Signature Equity Partners's FLNA Position: Q2 2026 in Review

Signature Equity Partners held its Filana Therapeutics (FLNA) position steady in Q2 2026 at 2,000 shares worth $2.38K. The position accounts for ﹤0.01% of the portfolio, ranked #1148.

Signature Equity Partners first reported a position in FLNA in Q4 2025 and has held it in 3 quarters since. The position peaked at $3.96K in Q4 2025. 85 funds tracked by Wall St. Rank hold FLNA as of Q2 2026.

  • Signature Equity Partners held 2,000 shares of Filana Therapeutics worth $2.38K as of Q2 2026.
  • Signature Equity Partners left its Filana Therapeutics share count unchanged in Q2 2026.
  • Filana Therapeutics made up ﹤0.01% of Signature Equity Partners's portfolio in Q2 2026, its #1148 holding.
  • Signature Equity Partners first reported a position in Filana Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Signature Equity Partners's Filana Therapeutics position peaked at $3.96K in Q4 2025.
  • 85 funds tracked by Wall St. Rank held Filana Therapeutics as of Q2 2026.

Based on Signature Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.